Lee Chunwoo, You Dalsan, Yoo Sangjun, Song Cheryn, Hong Bumsik, Hong Jun Hyuk, Ahn Hanjong, Kim Choung-Soo
Department of Urology, Gyeongsang National University Changwon Hospital, Gyeongsang National University School of Medicine, Changwon, Korea.
Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
J Cancer Res Clin Oncol. 2016 Jul;142(7):1651-7. doi: 10.1007/s00432-016-2172-x. Epub 2016 May 19.
This study was designed to evaluate and compare the oncological outcomes of patients with pathological T1a (pT1a) small renal cell carcinomas (RCCs) with those with incidental pathological T3a (pT3a) RCCs who have been treated using partial nephrectomy (PN).
We retrospectively evaluated the records of 1367 consecutive patients who underwent PN for small RCCs (≤4 cm) between 1997 and 2014. The curves for recurrence-free, cancer-specific, and overall survival were estimated using the Kaplan-Meier method. Cox regression analysis was used to estimate the prognostic significance of each variable.
Of the 1367 small RCC patients identified, 1324 (96.8 %) had pT1a lesions and 43 (3.2 %) had pT3a lesions. The median ages of the pT1a and pT3a patients were 53.9 and 58.1 years, respectively. Patients received follow-up for a median of 54 months. The 5- and 10-year RFS rates in patients with pT1a and pT3a RCCs were 98.0 and 95.2 %, and 94.4 and 95.2 %, respectively (P = 0.521). None of the patients with recurrent tumors in the pT3a group have died by the time of the writing of this report. A multivariate Cox proportional hazards model showed that tumor size was a significant predictor of RFS and CSS (P < 0.05). However, pT stage (pT3a vs. pT1a) was not a significant predictor of RFS, CSS, or OS (P = 0.104, P = 0.573, and P = 0.441, respectively).
Our study found that pT3a stage disease following PN for small RCCs (≤4 cm) had similar oncological outcomes to those of pT1a stage.
本研究旨在评估和比较接受部分肾切除术(PN)治疗的病理T1a(pT1a)期小肾癌(RCC)患者与偶然发现的病理T3a(pT3a)期RCC患者的肿瘤学结局。
我们回顾性评估了1997年至2014年间连续1367例因小肾癌(≤4 cm)接受PN治疗患者的记录。采用Kaplan-Meier法估计无复发生存、癌症特异性生存和总生存曲线。使用Cox回归分析估计各变量的预后意义。
在1367例确诊的小肾癌患者中,1324例(96.8%)为pT1a期病变,43例(3.2%)为pT3a期病变。pT1a期和pT3a期患者的中位年龄分别为53.9岁和58.1岁。患者中位随访54个月。pT1a期和pT3a期RCC患者的5年和10年无复发生存率分别为98.0%和95.2%,以及94.4%和95.2%(P = 0.521)。在撰写本报告时,pT3a组中没有复发性肿瘤患者死亡。多因素Cox比例风险模型显示,肿瘤大小是无复发生存和癌症特异性生存的显著预测因素(P < 0.05)。然而,pT分期(pT3a与pT1a)不是无复发生存、癌症特异性生存或总生存的显著预测因素(分别为P = 0.104、P = 0.573和P = 0.441)。
我们的研究发现,对于小肾癌(≤4 cm)接受PN治疗后处于pT3a期的疾病,其肿瘤学结局与pT1a期相似。